Adrian Hayday IJonathan Edgeworth IManu Shankar-Hari KCL … · 2020. 5. 29. · Adrian...
Transcript of Adrian Hayday IJonathan Edgeworth IManu Shankar-Hari KCL … · 2020. 5. 29. · Adrian...
Covid–ImmunoPhenotyping - a preliminary data release, May 22, 2020
Adrian Hayday I Jonathan Edgeworth I Manu Shankar-HariKCL I CIDR I GSTT I ICU I CRICK
Summary
• Our initial high throughput in-depth analysis of over 60 hospitalised Covid-19 patients and over 50 controls has revealed:
1. An immunological signature of Covid-19 disease2. Several discrete components of that signature that track with severity
Potential importance• SARS-Cov-2 virus is not the threat to global stability; that threat stems from the
seriousness of the disease that the virus has the potential to cause
• Understanding the basis for serious disease symptoms may permit new approaches to diagnosis and therapy that may considerably reduce the risk that infection by SARS-CoV-2 would lead to severe, potentially fatal disease.
www.immunophenotype.org
Scene setting
• Despite most exposures being pauci-symptomatic, Covid-19 has been the most socially-transformative infectious disease in living memory - Millions infected; hundreds of thousands dead or only gradually recovering from severe disease -Precipitous burden on health care.
• The virus has not gone away – major rises in global infections continue to be reported, and may “re-surge” in autumn. Effective anti-virals and vaccination are still in development.
• Serious symptoms have been associated with underlying morbidities, age and gender, but are there other factors?
• Serious symptoms are clinically associated with lymphopenia, CRP, and some other metrics, but what mechanisms and processes do these reflect?
www.immunophenotype.org
Hypothesis for Covid-IP• The immune system lies at the heart of the host-pathogen relationship and may
track with and/or underpin disease course.
Key questions• Can we identify biologically meaningful markers or ‘immune signatures’ that predict
disease course at the front door?
• Can we identify ‘immune signatures’ in patients who do well? This will guide us toward “correlates of protection”, informing vaccine design and helping to predict the likely efficacy of current or proposed medications that can be re-purposed?
• What is the relative contribution to sustained protection of T cells versus antibody production?
• What is the nature of covid-19 lymphopenia and what are its implications - an impact on innateàadaptive switch?
www.immunophenotype.org
The Covid-IP Pipeline *
Day 1, 3, 9Co-ordination with other studies Serology; IgG/IgM [S/RBP/N]
ELISA- Dr Katie DooresLIPS – Professor Pärt Peterson (Tartu)
• Legendplex assay – plasma cytokines, inc. IL-6, IL-8, IP10, IL10
• Additional analytes, including Tryptophan metabolites.
• Autoantibodies
8 panel flow cytometry on fresh specimens to measure cell types,cell status, and cell cycling
Individual CD4 and CD8 T cellsare sorted and DNA extracted for T cellReceptor repertoire sequencing
Heparin
PAXgene for RNA
Plasma
Leukocytes
Biobank storage for future projects
Research Nurse
Collections
*facilitated by the King’s College Infectious Diseases Biobank
The COVID-IP cohort:hospitalized SARS-CoV-2 infected patients, ~80% of whom recovered without intensive care, and 20% of whom declined, with ~10% declined irreversibly.
Clinical conditions were classified according to a combination of local clinical practice and WHO classifications.
www.immunophenotype.org
What we have learnedThis is a preliminary data-set, made broadly available in the hope that it can guide and/or inform others internationally. More formal peer-reviewed data releases will follow, respectful of compliance with appropriate scientific standards.
www.immunophenotype.org
Covid-19: highly selective diminution of T cells, associated with disease but not obviously with severity
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●●●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●●
●●
●
●
●●
●
●●
●●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●●●
●
●
●●
●●
0.0e+00
5.0e+05
1.0e+06
1.5e+06
Healthy Low Moderate SevereWHO_Severity
Time_02.Cells_02.Singlets1_02.Singlets2_02.Live_02.CD45p_02.T_02_Count_back
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
# T
cells
ns****
****
Measures of statistical significance between designated samples
A decrease in blood T cell numbers(T cell lymphopenia) is characteristic of
Covid-19 disease, as is true in several other infections. However, it shows only a weak correlation with disease severity.
This is a T cell-focused phenomenon since B lymphocyte numbers and NK
cells are largely preserved
T cells are one of the major components of the adaptive immune system.
CD4+ Helper T (Th) cells help to shape, activate and regulate the adaptive immune response by activating other immune cells,
releasing cytokines, and helping B cells produce antibodies.
CD8+ Cytotoxic T cells recognise and directly kill virus-infected cells.
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●●
●
●●
●●●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
● ●
●
●
●●
●●
0.0e+00
2.5e+05
5.0e+05
7.5e+05
Healthy Low Moderate SevereWHO_Severity
Time_02.Cells_02.Singlets1_02.Singlets2_02.Live_02.CD45p_02.T_02.CD4_02_Count_back
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
# CD
4+T
cells
ns****
****
●●●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
●
●
●●●
●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●●
●●●
●●
●●
●●●
●●
●
●●
●●
●●
●●
●
●
●
●●
●
●●
●●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●●●●● ●
●●●
●
●
●
●
●
●
●●0e+00
1e+05
2e+05
3e+05
4e+05
Healthy Low Moderate SevereWHO_Severity
Time_02.Cells_02.Singlets1_02.Singlets2_02.Live_02.CD45p_02.T_02.CD8_02_Count_back
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
# CD
8+T
cells
ns****
***
Covid-19: both Helper and Cytotoxic T cells are diminished with disease, with some link to severity
Covid-19: T cell lymphopenia is selective: T helper (Th) cell subsets are differentially affected
The impact on CD4+ Helper T cells is selective Th1, Th17.1 cells are diminished, while Th2 and Th17 are relatively unaffected
●● ●●
●
●●●
●
●
●
●●
●
●
●●
●
●
●
●●
●●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
● ●
●
●
●●
●●
●
●
●
●
●
●●●
●
●●●●
●●
●
●●
●
●●●
●
●●
●
●
●●
●●
●
●●
●●
●
●
●●
●
●
●
●
●
●
●●
●
●●
●
●
●●
●
●
●●
●
●
●
●●
●
●
●
●
●
●●●
●●
●●
●●●
●
●●0.0e+00
5.0e+04
1.0e+05
1.5e+05
Healthy Low Moderate SevereWHO_Severity
Time_02.Cells_02.Singlets1_02.Singlets2_02.Live_02.CD45p_02.T_02.CD4_02.CD4_CXCR3p_02.CD4_Th17.1_02_Count_back
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
# Th17.1 cells
ns
*******
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●●
●
●
●●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●●
●●●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
● ●
●
●●
●●
●
●
●
●
●●
●
●●
●
●●
●● ●
●
●
● ●
●
●
●●
●
●
●
●
●●
●
●
●●
●
●●
●●
●●
●
●●
●
●●0.0e+00
5.0e+04
1.0e+05
1.5e+05
2.0e+05
Healthy Low Moderate SevereWHO_Severity
Time_02.Cells_02.Singlets1_02.Singlets2_02.Live_02.CD45p_02.T_02.CD4_02.CD4_CXCR3p_02.CD4_Th1_02_Count_back
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
# Th1 cells
ns
****
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●
●●
●●●
●●
●
●●●
●
●
●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●
●
●
●
●
●●
●●
●
●
●
●●●
●
●●
●
●
●
●●
●
●
●●●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
0.00e+00
2.50e+04
5.00e+04
7.50e+04
1.00e+05
1.25e+05
Healthy Low Moderate SevereWHO_Severity
Time_02.Cells_02.Singlets1_02.Singlets2_02.Live_02.CD45p_02.T_02.CD4_02.CD4_CCR4p_02.CD4_Th2_02_Count_back
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
# Th2 cells
ns
nsns
●●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
●●
●
●
●
●
●
●●●
●
●
●
●●
●●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●● ●
●
●
●
●●●●
●
●
●
●●●
●
●
●
●●●●
●●●
●
●
●●●●
●
●●
●●
●
●
●●
●
●
●
●
●
●
●
●●●
●
●
●
●●
●●
●
●
●
●
●
●
●●
●
●
●●●●
●
●
●
●
●●
●●
●
●
●●
0.0e+00
5.0e+04
1.0e+05
1.5e+05
2.0e+05
Healthy Low Moderate SevereWHO_Severity
Time_02.Cells_02.Singlets1_02.Singlets2_02.Live_02.CD45p_02.T_02.CD4_02.CD4_CCR4p_02.CD4_Th17_02_Count_back
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
# Th17 cells
ns
nsns
Covid-19: Other CD4+T cell subsets are also differentially affected
●●●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●●
●
●●
●●
●
●●●
●
●
●
●●●
●
●●
●●
●
●
●●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●●
●●
●●
●
●●
●●●
●
●●
●
●●
●●●●
●●0.0e+00
5.0e+04
1.0e+05
1.5e+05
Healthy Low Moderate SevereWHO_Severity
Time_02.Cells_02.Singlets1_02.Singlets2_02.Live_02.CD45p_02.T_02.CD4_02.CD4_CD45RAn_CCR7n_02_Count_back
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
CD4 TEM
ns
****
●●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●●●
●
●●
●
●●
●
●
●
●●●
●
●
●●●●
●
●●
● ●●
●
●●
●●
●
●
●
●
●●●●
●
●
●
● ●
●
●
●
●
●
●
●
●
●●
●
●●
●
●●
●
●
●
●●●
●
●
●
●
●●
0e+00
2e+05
4e+05
6e+05
Healthy Low Moderate SevereWHO_Severity
Time_02.Cells_02.Singlets1_02.Singlets2_02.Live_02.CD45p_02.T_02.CD4_02.CD4_CD45RAn_CCR7p_02_Count_back
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
CD4 TCM
ns
**
●●●●
●
●
●●●●
●●
●● ●
●●
●●●●●
●●●●●
●
●●●●
●
●●
●●
●
●
●●
●
●
●●●
●
●●
●●
●●
●
●●●●
●
●
●
●
●
●
●
● ●● ●●●●
●●●
●
●
●●●
●
●●
●
●●
●
●
●
●
●●
●
● ●
●
●●●● ●●●●
●●●●●●
●●
●
●●
●●●●
●
●
●●
●
●
●●●●
●
●●●●●● ●●●
●
●
●●●●
●●0e+00
2e+04
4e+04
6e+04
8e+04
Healthy Low Moderate SevereWHO_Severity
Time_02.Cells_02.Singlets1_02.Singlets2_02.Live_02.CD45p_02.T_02.CD4_02.CD4_CD45RAp_CCR7n_02_Count_back
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
CD4 TEMRA
ns
nsns
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●● ●●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●●
●
●
●●●●●
●
●
●
●
●
●
●
●●●
●
●
●●
●
●
●
●●
●●●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
● ●
●
●●
●●
●
●●
●
●
●
●
●
●
●
●
●●
●
●●
●
●●
●●
●
●
●
●●
●
●
●
●●
●●
●
●
●
●
●
●
●●●
●
●●
●●
0.0e+00
2.5e+05
5.0e+05
7.5e+05
Healthy Low Moderate SevereWHO_Severity
Time_02.Cells_02.Singlets1_02.Singlets2_02.Live_02.CD45p_02.T_02.CD4_02.CD4_CD45RAp_CCR7p_02_Count_back
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
CD4 TN
ns
*****
Naïve T (TN ) cells have not yet encountered their specific, and
antigen are usually resting
TEMRA - terminally differentiated effector
memory cells - are temporarily exhausted
Central Memory T (TCM) cells act as a reservoir of our response to secondary
infections
Effector Memory T ( TEM ) cells will interact with host cells to
carry out their immune function
Reduced levels of CD4naive and CD4EM in Covid-19, while CD4CM, and CD4EMRA cells are largely protected
Covid-19 : The impact on CD8+ T cells is also selective
●●●●●●●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●●
●
●
●
●
●
●
●●
●●●●●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●
●●
●
●
●●●●●
●
●
●
● ●
●
●●
●
●
●
●
●
●
●
●●
●●●
●●
●●●●
●
●
●●
●
●●
●
●
●●●●
●
●
●
●
●
●●● ●●● ●●●●●●
●●●●●
● ●
●
●
●
●●0.0e+00
2.5e+04
5.0e+04
7.5e+04
1.0e+05
Healthy Low Moderate SevereWHO_Severity
Time_02.Cells_02.Singlets1_02.Singlets2_02.Live_02.CD45p_02.T_02.CD8_02.CD8_CD45RAn_CCR7n_02_Count_back
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
CD8 TEM
ns
*****
●●●●
●
●
●●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●●
●
●
●
●
●
●
●●●
●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●
●
●
●●
●●
●
●●
●
●●
●
●
●●●●
● ●
●
●●
●
●●
●
●●
●
●
●
●
●
●●
●●
●
●●
●●
●
●
●●
●
●
●
●
●
●●
●●●●●●
●
●
●
●
●
● ●●
●●
●●
●●
●● ●●●●
●●
●●
●●
●
●●
0e+00
1e+04
2e+04
3e+04
4e+04
5e+04
Healthy Low Moderate SevereWHO_Severity
Time_02.Cells_02.Singlets1_02.Singlets2_02.Live_02.CD45p_02.T_02.CD8_02.CD8_CD45RAn_CCR7p_02_Count_back
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
CD8 TCM
ns
***ns
●●
●
●
●
● ●
●●●
●●
●●
●
●●
●
●●
●
●
●●●
●
●
●●●
●●
●●●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●●●●
●
●●
●
●
●
●
●
●
● ●
●
●
●●
●
●
●
●
●●
●●
●
●●
●●
●●
●●
●
●
●●
●
●●
●●
●
●
●●●
●
●
●
●
●
●
●●●●
●
●●●●●●
●●●
●
●
●
●
●●
●●0e+00
1e+05
2e+05
3e+05
Healthy Low Moderate SevereWHO_Severity
Time_02.Cells_02.Singlets1_02.Singlets2_02.Live_02.CD45p_02.T_02.CD8_02.CD8_CD45RAp_CCR7n_02_Count_back
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
CD8 TEMRA
nsns
**
●●●●●●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
● ●
●●
●
●
●
●
●
●
●●
●
●
●
●●●●●
●●
●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●● ●●●
●●
●
●
●●
●
●
●●
●
●●
●
●
●
●
●
●●
●●●
●
●
●
●
●●●●
●●●●●●●●
●●●
●● ●●
●●0.0e+00
5.0e+04
1.0e+05
1.5e+05
2.0e+05
2.5e+05
Healthy Low Moderate SevereWHO_Severity
Time_02.Cells_02.Singlets1_02.Singlets2_02.Live_02.CD45p_02.T_02.CD8_02.CD8_CD45RAp_CCR7p_02_Count_back
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
CD8 TN
ns****
As for CD4 cells, CD8naive and CD8EM cells are reduced in Covid-19; but no clear link to severity
TEMRA - terminally differentiated effector
memory cells - are temporarily exhausted
Central Memory T (TCM) cells act as a reservoir to our response to secondary
infections
Effector Memory T ( TEM ) cells will interact with host cells to
carry out their immune function
Naïve T (TN ) cells have not yet encountered their specific, and
antigen are usually resting
Covid-19: remaining T cells, although low in numbers, are actively traversing the cell cycle and this is linked to severity
●●
●
●
●●●●● ●●●●●●●●●●
●●●●
●●
●●●●
●
●●
●●
●
●●●
●●●●
●
●
●●●●●
●●
●
●
●●
●
●
●
● ●●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●●●●●
●●
●●●
●
●
●
●●
●
●
●●
●
●●
●
●
●●
●
●
●
●
●
●
●●
●
● ●
●
●●●
●
●
●●
●
●
●
0
10
20
30
40
50
60
70
Healthy Low Moderate SevereWHO_Severity
G1_5_CD8_CD45RAn_CCR7n_5_freq
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
●
●
●
●●
●●●●●
●●●●●● ●● ●●
● ●●●●●●●●
●●●●●●●●●●●●●
●
●● ●●●●
● ●
●
●
●● ●●
●
●●●●
●●
●
●
●●
●●
●
●
●
●●
●
●
●
●
●●●●●
●●
●
●●
●
●
●
●
●
●
●
●
●
●●
● ●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
● ●● ●
●
●
●
●
●
●
0
10
Healthy Low Moderate SevereWHO_Severity
S_G2_M_5_CD8_CD45RAn_CCR7n_5_freq
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
% G
1 CD
8 T E
M
% S
/G2/
M C
D8 T
EM
****
***
ns***
*
●
●
●
●
●
●●
●
● ●●●●
●●
●
● ●●●
●
●●
●
●
●●●●
●
●●
●
●
●
●●●●●
●
●
●
●●●
●
●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●●
●
●
●●
●
●
●
0
10
20
30
40
Healthy Low Moderate SevereWHO_Severity
G1_5_CD4_CD45RAn_CCR7n_5_freq
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
% G
1 CD
4 T E
M
% S
/G2/
M C
D4 T
EM
●
●
●
●
●●
●●● ●●●● ●●
●
●●●
●●●
●●●●●●●
●
●●●●●
●●●●●●●
●●●●●●●
●
●
●
●
●●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
● ●●
●●
●●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●●
●
●
●
●
●
● ●
●
●●
●
●
●
0
5
Healthy Low Moderate SevereWHO_Severity
S_G2_M_5_CD4_CD45RAn_CCR7n_5_freq
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
*****
****
****
Cell cycle
Covid-19: a collapse of Vδ2 T cells is a disease signature, that is particularly striking in some patients
●
●
●
●●
●●
●
●●●●
●
●
●
●●●
●
●
●●
●
●
●
●
● ●
●
●
●
●●●
●
●
●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●●
●●●
●
●
●●
●
●
●●
●
●●
● ●
●
●
●
●●
●
●
●
●●
●
●●
●
●
●
●●
●●
●
●
● ●●●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
0
10
20
30
40
50
60
70
80
Healthy Low Moderate SevereWHO_Severity
gd_Vd1_03.gd_03_freq
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
% Vd 1
+T
cells
(of gd )
ns**
**
●
●
●
●●
●
●
●
●
●●
● ●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●●
●
●
●
●● ●
●
●
●
●●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●●●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●
●
●
●
●
●
●●
●
●●
●●
●
●●
●●
●
●
●
●
●
●●
●●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●●
●
●
●
●
●
●
●
0
10
20
30
40
50
60
70
80
90
Healthy Low Moderate SevereWHO_Severity
gd_Vd2_03.gd_03_freq
class_WHO_severityHealthy
Low
Moderate
Severe
class_status_detailed●
●
●
●
●
●
●
CF
control
COVID
COVID_deceased
IMMERSE
Recovered_confirmed
Recovered_suspected
% Vd2
+T
cells
(of gd )
ns****
***
gδ TCR+ T cells express a γδ-TCR rather than the αβ-TCR on the cell surface, and
are a predominant lymphoid population in body surfaces such as the lung which is targeted by SARS-Cov-2.
There is a collapse in numbers of the predominant blood gd cells type (Vd2+). Conversely, Vδ1+ T cells show increased representation and their active cycling
is severity associated (not shown).
Innate immunity markers
www.immunophenotype.org
Loss of basophils from the blood appears as a biomarker of COVID-19 severity
Basophils assessed via flow cytometry [gated as non-PMN based on ssc and then CD3neg, CD19neg,HLADRneg, CD14neg, CD123+]
Basophils are potentially disease-relevant because of their homing to the lung, wherein Covid-19 disease is manifest, and because of their implication in regulating blood coagulation
Basophils via flow cytometry
****
% B
asop
hils
(of l
ive
cells
)
****
WHO_Severity
• Cell cycling of CD4EM , CD4CM , CD8EM , Vd1 cells• Depletion of specific CD4 and CD8 T cell subsets• Basophil counts crashing• Neutrophil counts increasing• Crash in plasmacytoid dendritic cells• Sustained IL6, IP10, IL10• CRP
Other major changes, e.g. including plasmablastexpansion, major changes in monocyte populations; reductions in CD5+ B cells, change in DC phenotypes,
and production of antibodies compose a disease-associated signature
but are not obviously linked to severity
In sum, several biomarkers of COVID-19 severity are emerging
Basophils via flow cytometry
****
% B
asop
hils
(of l
ive
cells
)
****
WHO_Severity
Take home messages• Phenotyping à define perturbations in immunityà design a ‘panel’ of descriptive
markers tied to severe disease à prospectively evaluated as a predictive score for severity à clinical endpoint e.g. decision aid for early ICU admission
• Phenotypingà insight into disease pathologyà ongoing investigation into what drives T lymphopenia and how this impacts on memory responsesà informs Vaccine design
• Data will be freely available on www.immunophenotype.org.
• Applications alongside GSTT clinical trials e.g. phenotyping before and after therapeutic interventions (e.g. IL7, anti-IL6) à mechanism of action
www.immunophenotype.org
Acknowledgements
All ward staff and infection departmentAll project PI’s for RECOVERY/IMMERSE/ISARIC/ACT
King’s Infectious Diseases BiobankJohn CasonChristine Mant
Adrian HaydayJonathan EdgeworthManu Shankar-Hari
Irene del Molino del BarrioIsaac Franco QuijornaJosh FreedmanKatie Doores
Eva Bugallo BlancoJulie ChanRozalyn YorkeSarah GeeSarah RyanThomas Hayday
Centre for Clinical Infection and Diagnostics Research (CIDR) - GSTT NHS Foundation Trust
Amy DayKaren BisnauthsingKate BrooksLauren MartinezBlair Merrick
John Black Trust
Manu Shankar-Hari lab at KCLMatthew FishAislinn Jennings
Hayday lab at The CRICK, KCL and CIBCI
Abhishek DasAdam LaingAnna LorencDaniel DaviesDuncan MckenzieEfstathios TheodoridisFernanda Kyle Florencia CanoFurqan Shah
Iva ZlatarevaLeticia Monin AldamaMagdalene JosephMiguel Muñoz-RuizPierre VantouroutRichard DavisShraddha KamdarVassia SofraYin Wu
Kola BabalolaFederico López GómezJeremy MasonVioletta MuñozJonathan Warren
Sara Cipolat
Institute of Molecular Biology and Pathology (CNR-Italy)Francesca Di Rosa
Kai KisandPärt Peterson
UNIVERSITY OF TARTU (Estonia)
GSTT-King’s Biomedical Research CentreMatthew Brown Richard Ellis
Visit here for full list of Team Members & Collaborations
www.immunophenotype.org